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doi:10.1016/j.jmii.2010.08.004Background: Clinical information about bacteremia due to extended-spectrum b-lactamase
(ESBL)-producing pathogens in cancer patients was limited. The study was aimed to identify
the clinical manifestations and risk factors for mortality in ESBL-producer bacteremia in cancer
patients.
Methods: A retrospective study of bacteremia caused by ESBL-producing Escherichia coli or
Klebsiella pneumoniae in adults with cancer in National Cheng Kung University Hospital and
National Taiwan University Hospital from July 2002 to August 2007 was conducted. Clinical
characteristics, initial manifestations, and antimicrobial therapy were analyzed for their asso-
ciation with crude mortality at 14 days after bacteremia onset.
Results: A total 113 episodes of bacteremia caused by E coli (59.3%), K pneumoniae (39.8%) or
both (0.9%) were included. Patients with hematological malignancy were younger (55 22 vs.
69 14 years, p< 0.003) and had less co-morbidity, but were more likely to have neutropenia
(73.1% vs. 4.6%, p< 0.001) than those with solid tumor. By the univariate analysis in 113fectious Disease, Department of Internal Medicine, National Cheng Kung University Hospital, No. 138,
u.edu.tw (W.-C. Ko).
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b-lactamase producer in cancer patients 283episodes of ESBL-producer bacteremia, several risk factors, including pneumonia or soft-tissue
infection as the bacteremia source, initial manifestations with high Pitt bacteremia scores,
shock, respiratory failure or severe sepsis, and inappropriate definitive therapy were associ-
ated with 14-day crude mortality. By multivariate analysis, only pneumonia [adjusted odds
ratio (AOR), 5.2; 95% confident interval (CI), 1.3e21.0; pZ 0.021], severe sepsis (AOR, 24.3;
95% CI, 5.6e105.0; p < 0.001), and inappropriate definitive therapy (AOR, 11.3; 95% CI,
1.7e72.8; pZ 0.011) were independently associated with a fatal outcome.
Conclusion: The presence of neutropenia or underlying hematological malignancy in cancer
patients with ESBL-producer bacteremia was not associated with an increase in the mortality
rate. Appropriate definitive antimicrobial therapy will be beneficial in improving clinical
outcome.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Although many potent and broad-spectrum antibiotics had
been marketed in the past decades, bacterial infections still
caused substantial mortality and morbidity among cancer
patients with or without neutropenia. This may be related to
more immunosuppressant medications and aggressive diag-
nostic or therapeutic tools in clinical management of various
cancers. Gram-positive bacteria were predominant causa-
tive pathogens of bloodstream infections in cancer patients
in western countries,1 but Gram-negative bacilli could cause
severe sepsis and mortality. Enterobacteriaceae, especia-
lly Escherichia coli and Klebsiella pneumoniae, remain
the prevalent causes of bacterial infections in cancer
patients.2e5 Extended-spectrum b-lactamase (ESBL)-pro-
ducing pathogens were considered to be related to a poor
outcome.6 The recognized risk factors for acquisition of
ESBL-producing pathogens included previous antibiotics
use, longer hospital stay, and intravascular devices, which
were also characteristic in cancer patients.7e9 Besides, the
trend of increasing ESBL-producer bacteremia has been
a great concern due to increasing medical expenditure and
mortality.6 Variable severity and outcome were observed in
individuals with ESBL-producer bacteremia. There were few
studies discussing in ESBL-producing bacteremia in cancer
patients so far.10,11 We are intended to identify clinical
features and risk factors for the mortality in cancer patients
with ESBL-producer bacteremia.
Methods
The retrospective cohort study was conducted at National
Cheng Kung University Hospital and National Taiwan Uni-
versity Hospital in Taiwan, two medical centers with 1,100
and 2,000 beds, respectively. The study period was May 2002
through August 2007. All eligible patients were identified
retrospectively through the records of clinical microbiology
laboratory at both centers, where ESBL production was
detected by the screening and then phenotypic confirmatory
tests according to those recommended by the Clinical and
Laboratory Standards Institute (CLSI).12 Patients older than
18 years who had underlying malignancy and ESBL-producing
E coli or K pneumoniae bacteremia were included. Growth of
the same organism in blood cultures after at least 4 weeks
from the initial bacteremia episode was considered to bea new infectious episode. The primary outcome in the study
is the 14-day crude mortality rate, and crude mortality rate
is defined as the rate of all death after bacteremia onset.
Data collection
Retrieved from medical chart records was clinical informa-
tion, including sex, age, classification of malignancy type,
clinical manifestations, co-morbidity, primary site of infec-
tion, serum biochemistry, laboratory data, antimicrobial
therapy, and clinical outcome. Besides, host factors regar-
ded as being immunosuppressive, such as systemic steroid,
immunosuppressant therapy, neutropenia status, were also
recorded.
Definitions
Hematological malignancies referred to the types of cancer
that affect blood, bone marrow, and lymph nodes, and solid
tumors were malignant tumors that develop in virtually any
tissue or organ. ESBL-producer bacteremia is the bacteremic
episode due to E coli or K pneumoniae with ESBL production
phenotypically detected according to the CLSI criteria.12
Breakthrough bacteremia was defined as the development
of bacteremia caused by the same ESBL-producer while at
least one in vitro active antimicrobial agent has been used
for at least 5 days. Recent immunosuppressant therapy
included corticosteroid use (10 mg or an equivalent dosage
daily dosage) for more than 2 weeks, and chemotherapy or
anti-rejected therapy within 4 weeks before bacteremia
onset. Neutropenia was defined as absolute neutrophil
counts less than 500/mm3 at the bacteremia onset. Pitt
bacteremia score was measured at the bacteremia onset to
evaluate the severity of bacteremia.13 Extreme body
temperature (BT) indicates BT below 36C or more than
39C. Organ dysfunction was defined according to organ
dysfunctions and/or infection model, and categorized as
respiratory, cardiovascular, renal, neurologic, hepatic, or
hematological failure.14 Severe sepsis means sepsis associ-
ated with organ dysfunction, hypoperfusion, or hypotension
which could be reversed after adequate fluid resuscitation.15
Thedate of thefirst positive bloodculturewas regardedas
the date of bacteremia onset. Antibiotic therapy was
considered to be appropriate, if the prescribed antibiotic
was in vitro active against the causative organism. Antibiotic
284 S.-S. Wang et al.therapy was classified as empirical or definitive therapy. The
former was defined as antimicrobial agents given before the
susceptibility result was available, and the latter as antimi-
crobial agent adjusted after the susceptibility data are
available.
Statistical analysis
All statistical data were analyzed with SPSS software, version
13.0 for Windows (SPSS Inc, Chicago, IL, USA). Continuous
variables were compared by Student t test while categorical
variables were compared by c2 test or two-tail Fisher’s exact
test. The p values <0.05 were considered to be statistically
significant. Variables considered significant in univariate
analysis were the candidates included in multivariate anal-
ysis. Logistic regression analysis was used to identify the
independent risk variables for mortality. The KaplaneMeier
method was used for the survival analysis.
Results
Study population
A total of 113 (32.2%) episodes of ESBL-producer bacteremia
in patients with underlying malignancy were identified
among 351 episodes of bacteremia due to ESBL-producing
E coli and K pneumoniae during the study period. Clinical
characters of 113 episodes among 110 patients were shown
in Table 1. There were two major types of malignancy.
Hematological malignancy included leukemia or lymphoma,
and solid tumors a variety of malignancies, such as lung,
colon, liver, breast, gastric, or bile duct cancer. Twenty-six
(23%) episodes occurred in patients with hematological
malignancy and 87 (77%) episodes solid tumors. Their mean
age among them was 65 18 years. Patients with hemato-
logical malignancy were younger than those with solid
tumor (53 vs. 68 years respectively, pZ 0.003). Neu-
tropenia was present in 20.4% of all patients, and 82.6%
occurred in patients with hematological malignancy.
Although co-morbidities, including diabetes mellitus (0% vs.
29.9%, p< 0.001), chronic kidney disease (0% vs.18.4%,
pZ0.021), or liver cirrhosis (0% vs. 18.4%, pZ 0.021), were
less often noted in patients with hematological malignancy,
more immunosuppressant therapy, such as chemotherapy
(84.6% vs. 18.4%, p< 0.001) and steroid (30.8% vs. 10.3%,
pZ 0.024) was recently used in these patients. The severity
of bacteremia, as indicated by severe sepsis (pZ 0.45) or
Pitt bacteremia score (4 points, pZ 1.0) did not vary
significantly between two patient groups.
Empirical carbapenemtherapywas prescribedmore often
to patients with hematological malignancy than those with
solid tumors (53.8% vs. 32.2%, pZ 0.064). Administration of
appropriate empirical therapy wasmore frequent in patients
with hematological malignancy, though the difference is not
statistically significant (57.7% vs. 40.2%,pZ 0.123).
Mortality and predictors of outcome
Of 113 episodes, 27 (24%) episodes died within 14 days after
onset of bacteremia. The mortality rate of ESBL-producingE coli was 19.4% and K pneumoniae was 28.8% (pZ 0.26).
The primary outcome, 14-day mortality rate, of those with
solid tumors, tended to be higher than that of hematolog-
ical malignancy (37.6% vs. 11.5%, pZ 0.12). Of 79 mono-
microbial bacteremic episodes, 20 (25.3%) died within 14
days, and 7 (20.6%) of 34 polymicrobial episodes did
(pZ 0.064) (Table 2).
By the univariate analysis, factors associated with 14-day
mortalityamongESBL-producerbacteremiawerepneumonia,
urosepsis, skin and soft-tissue infection, respiratory failure,
shock, extreme BT, severe sepsis, higher Pitt bacteremia
score, appropriate definitive therapy, and carbapenem use
(Table 2). The presence of inappropriate empirical therapy,
polymicrobial bacteremia, fluoroquinolone (levofloxacin,
ciprofloxacin, or lomefloxacin) resistance, had no impact on
mortality. Multivariate analysis with a logistic regression
model found some independent factors positively associated
with mortality, including clinical presentations with severe
sepsis [adjusted odds ratio (AOR), 24.3; 95% confident interval
(CI), 5.6e105.0; p< 0.001] and pneumonia (AOR, 5.2; 95% CI,
1.3e21.0; pZ 0.021). The receipt of appropriate definitive
therapy was negatively associated with mortality (AOR, 0.1;
95% CI, 0.01e0.6; pZ 0.011) (Table 3). The survival curve
plotted by KaplaneMeier method did not showed a survival
benefit among those with appropriate versus inappropriate
empirical therapy (pZ 0.93, Fig. 1A). However, there is
a higher survival rate in patients with appropriate definitive
therapy than those with inappropriate definitive therapy
(p< 0.001, Fig. 1B).Discussion
Since human pathogens with ESBL production were identi-
fied in 1983, they had been found to distribute globally,7
and their clinical threat was increasing emphasized due to
multiple drug resistance and their adverse impact of
mortality.9,10 Specific clinical information of ESBL-producer
bacteremia in cancer patients is limited.10,11 Neutropenia
and recent immunosuppressant with steroid or chemo-
therapy have been reported as host factors associated with
increasing mortality in the cases of bacteremia,10,11 and
not surprisingly these factors or conditions were more
prevalent in patients with hematological malignancy. In
accordance with the finding that Gudiol et al. has demon-
strated that solid tumors as underlying disease wound
influence the mortality rate in ESBL-producing E coli
bacteremia,10 mortality rates, irrespective of sepsis-
related or crude mortality rates at 14 or 30 days after
bacteremia onset, there was a trend that patients with
solid tumors had a worse prognosis than those with hema-
tological malignancy. Younger age and less co-existing
chronic illness in individuals with hematological malignancy
were the possible reasons for such a finding. Another
relevant issue is that according to IDSA guideline, more
broad-spectrum b-lactam drugs would be prescribed for
febrile neutropenic cancer patients,3 and this clinical
practice promoted more and early use of carbapenems.
A carbapenem was used in 91% of neutropenic patients and
70% of non-neutropenic patients (pZ 0.04), and definitive
antimicrobial therapy was earlier shifted to appropriate
therapy among neutropenic patients than non-neutropenic
Table 1 Clinical characters and outcome of 113 episodes of bacteremia caused by extended-spectrum b-lactamase-producing
Escherichia coli or Klebsiella pneumoniae in adults with hematological malignancy or solid tumor
Characters Case no. (%) or mean SD p
Solid tumor
nZ 87
Hematology malignancy
nZ 26
Age (yr) 68.6 14.2 55.4 22.5 0.003
Elderly (age> 60 yr) 59 (67.8) 10 (38.5) 0.011
Male 44 (50.6) 17 (65.4) 0.262
Nosocomial infection 63 (72.4) 23 (88.5) 0.118
Co-morbidity
Diabetes mellitus 26 (29.9) 0 (0) <0.001
Liver cirrhosis 16 (18.4) 0 (0) 0.021
Chronic kidney disease 16 (18.4) 0 (0) 0.021
Recent chemotherapy 16 (18.4) 22 (84.6) <0.001
Steroid use 9 (10.3) 8 (30.8) 0.024
Chronic hemodialysis 5 (5.7) 0 (0) 0.588
Neutropenia (ANC< 500) 4 (4.6) 19 (73) <0.001
Organ transplantation 2 (2.3) 3 (10.3) 0.079
Source of bacteremia
Pneumonia 23 (26.4) 6 (23.1) 0.804
Urosepsis 22 (25.3) 2 (7.7) 0.06
Intra-abdomen infection 18 (20.7) 0 (0) 0.012
Primary bacteremia 12 (13.8) 14 (53.8) <0.001
Vascular catheter-related infection 11 (12.6) 3 (11.5) 1.000
Skin and soft-tissue infection 3 (3.4) 1 (3.8) 1.0
Pathogens
Escherichia coli 49 (56.3) 18 (69.2) 0.362
Klebsiella pneumonia 37 (38.1) 8 (30.8)
Both 1 0
Clinical manifestations
Shock 33 (37.9) 9 (34.6) 0.821
Extreme body temperaturea 5 (5.7) 7 (26.9) 0.006
Respiratory failure 19 (21.8) 3 (11.5) 0.395
Renal failure 18 (20.7) 3 (11.5) 0.395
Hepatic failure 21 (24.1) 4 (15.4) 0.428
Hematological failure 17 (19.5) 18 (66.7) <0.001
Neurological failure 8 (9.2) 1 (3.8) 0.682
Severe sepsis 25 (28.7) 5 (19.2) 0.45
Pitt bacteremia score 4 22 (25.3) 6 (23.1) 1.00
Laboratory data
Blood leukocyte, 1,000 cells/mm3 10.68 6.74 3.28 7.14 <0.001
Blood platelet, 1,000 cells/mm3 158.57 125.74 36.24 38.65 <0.001
Serum albumin, g/dL 2.9 0.68 3.12 0.53 0.328
Treatment
Appropriate empirical therapy 35 (40.2) 15 (57.7) 0.123
Empirical carbapenem 28 (32.2) 14 (53.8) 0.064
Appropriate definitive therapy 75 (86.2) 25 (96.2) 0.292
Outcome
ESBL breakthrough bacteremia 1 (3.8) 3 (3.4) 1.000
14-day crude mortality rate 24 (27.6) 3 (11.5) 0.118
Sepsis-related mortality rate 22 (25.3) 3 (11.5) 0.182
30-day crude mortality rate 30 (34.5) 5 (19.2) 0.157
a Body temperature below 36C or more than 39C.
ANCZ absolute neutrophil count; SDZ standard deviation.
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tropenia, although well known for predisposing to bacterial
infections in cancer patients, was commonly noted in
patients with hematological malignancy, but did not result
in a poor outcome.In concordance with several published reports that
mortality rate in ESBL-producing E coli or K pneumoniae
bacteremia was about 16e42%,10,11,16e19 the mortality rate
in the present study was 24%. Three independent prog-
nostic factors in our study were pneumonia as the source of
Table 2 Risk factors for 14-day crude mortality by univariate analysis of 113 episodes of bacteremia caused by extended-
spectrum b-lactamase-producing Escherichia coli or Klebsiella pneumoniae in adults with cancer
Episode number (%) p
Total, nZ 113 Survival, nZ 86 Fatal, nZ 27
Male 61 (54) 43 (50) 18 (66) 0.184
Elderly (age> 60 yr) 69 (61) 51 (59) 18 (67) 0.652
Underlying cancer
Solid tumor 87 (77) 63 (73) 24 (89) 0.118
Hematological malignancy 26 (23) 23 (27) 3 (11) 0.118
Recent chemotherapy 38 (34) 28 (33) 10 (37) 0.816
Neutropenia (ANC< 500 cells/mm3) 23 (20) 16 (19) 7 (26) 0.420
Organ transplant 5 (4) 4 (5) 1 (4) 1.000
Underlying condition other than cancer
Diabetes mellitus 26 (23) 22 (26) 4 (15) 0.303
Recent steroid therapy 17 (15) 11 (13) 6 (22) 0.233
Liver cirrhosis 16 (14) 12 (14) 4 (15) 1.000
Chronic kidney disease 16 (14) 11 (13) 5 (19) 0.528
Hemodialysis 5 (4) 4 (5) 1 (4) 1.000
Infection site
Pneumonia 29 (26) 15 (17) 14 (52) 0.001
Primary bacteremia 26 (23) 21 (24) 5 (19) 0.609
Urosepsis 24 (21) 22 (26) 2 (8) 0.058
Intra-abdomen infection 18 (16) 16 (19) 2 (8) 0.233
Vascular catheter-related infection 14 (12) 13 (15) 1 (4) 0.184
Skin and soft-tissue infection 4 (4) 0 (0) 4 (15) 0.003
Etiological pathogen
Escherichia coli 67 (59) 54 (63) 13 (48) 0.262
Klebsiella pneumonia 45 (40) 32 (37) 13 (48)
Polymicrobial infection 34 (30) 27 (31) 7 (26) 0.640
Fluoroquinolone resistance 87/106 67/81 20/25 1.000
Clinical manifestations
Hematological failure 35 (31) 24 (28) 11(13) 0.237
Hepatic failure 25 (22) 17 (20) 8 (30) 0.296
Renal failure 23 (20) 17 (20) 4 (15) 0.778
Respiratory failure 21 (19) 12 (14) 9 (33) 0.044
Neurological failure 9 (8) 5 (6) 4 (15) 0.214
Severe sepsis 30 (27) 11 (13) 19 (70) <0.001
Shock 42 (37) 23 (27) 19 (70) <0.001
Extreme body temperature 12 (11) 12 (14) 0 (0) 0.067
Pitt bacteremia score 4 28 (24) 16 (19) 12 (44) 0.010
Breakthrough bacteremia 4 (4) 2 (2) 2 (7) 0.241
Antimicrobial treatment
Appropriate empirical therapy 50 (44) 38 (44) 12 (44) 1.000
Appropriate definitive therapy 99 (88) 80 (95) 19 (70) 0.004
Empirical carbapenem use 42 (37) 33 (38) 9 (33) 0.820
Carbapenem use 83 (74) 68 (79) 15 (56) 0.024
ANCZ absolute neutrophil count.
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carbapenem as definitive therapy. The former two factors
were difficult to be amendable, but the prescription of in
time and appropriate antimicrobial therapy, according to
the in vitro susceptibility results from the clinical micro-
biology laboratory, can improve the short-term outcome of
cancer patients with ESBL-producer bacteremia. Although
the emergence of fluoroquinolone resistance has been
a concern as an independent prognostic factor in E coli and
K pneumoniae infections,11,20 the causative isolates in the
present study exhibited a high extent of fluoroquinoloneresistance (82%). However, fluoroquinolone resistance had
no significant impact on mortality in the study.
As for the source of E coli and K pneumonia bacteremia,
some studies revealed intra-abdominal infections heralded
a poor prognosis in affected patients.16,17 In accordancewith
a recently proposed score for the prediction of early death in
adults with cancer and bloodstream infections which high-
lighted the clinical significance in presence of pulmonary
infiltrates,21 pneumonia as the potential source of bacter-
emia, especially the presence of respiratory failure, inde-
pendently signified a grave outcome, and may justify the
Table 3 Independent risk factors for mortality in adults with bacteremia caused by extended-spectrum b-lactamase-
producing Escherichia coli or Klebsiella pneumoniae, based on multivariate analysis with logistic regression
Variables Adjusted odds ratio 95% confident interval p
Severe sepsis 24.29 5.62e104.98 <0.001
Pneumonia 5.20 1.29e20.95 0.021
Respiratory failure 3.45 0.40e29.89 0.261
Shock 2.81 0.43e18.42 0.280
Pitt bacteremia score 4 2.63 0.47e14.64 0.269
Appropriate empirical therapy 0.345 0.06e2.03 0.239
Appropriate definitive therapy 0.089 0.01e0.58 0.011
Variables with a p value< 0.05 in the univariate analysis, as well as the variables presumably to influence the mortality, i.e. appropriate
empirical therapy, neutropenia, or hematological malignancy, were the candidates for multivariate analysis.
b-lactamase producer in cancer patients 287early use of carbapenems for the life-threatening infections
caused by ESBL-producing Enterobacteriaceae.
Many studies evaluated the role of appropriateness anti-
microbial therapy in the outcome analysis and emphasizedFigure 1. Impact of appropriateness of empirical and
definitive antibiotics on 14-day survival rates analyzed by the
KaplaneMeier method. (A) Appropriateness of empirical anti-
microbial therapy had no impact on 14-day outcome
(pZ 0.93). (B) Inappropriate definitive therapy led to higher
mortality rate than appropriate definitive therapy (p< 0.001).the importance of appropriate empirical therapy.5,16,17
However, our study noted that initial inappropriate therapy
was not related to a grave outcome when compared with
initial appropriate therapy. However, it is important to
adjust antimicrobial therapy according to susceptibility
results, as echoed in two studies.10,17 Appropriate definitive
therapy for ESBL-producer bacteremia would be beneficial,
as evidenced in the present study.
In summary, the presence of neutropenia or the under-
lying hematological malignancy in cancer patients with
ESBL-producer bacteremia was not significantly associated
with an increase in the mortality rate. Appropriate defini-
tive antimicrobial therapy will be beneficial in improving
clinical outcome.
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